5alpha-苄基-12-羟基-2-异丙基麦角它曼-3,6,18-三酮甲烷磺酸酯 | 57884-92-1

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 麦角林及其衍生物
• 中文名称: 5alpha-苄基-12-羟基-2-异丙基麦角它曼-3,6,18-三酮甲烷磺酸酯
• 英文名称: (6aR,9R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic acid
• CAS: 57884-92-1
• 化学式: C36H43N5O8S
• 分子量: 705.8
• InChiKey: WECZKEGDCUZFPL-GRMMLOPMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.13
• 重原子数：
  50
• 可旋转键数：
  5
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  181
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• Cancer treatment via repositioned tricyclic anti-depressant-like drugs as anti-cancer agents and new combinations of such drugs
  申请人：Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

  公开号：US10695338B2

  公开（公告）日：2020-06-30

  Methods and compositions for treating a lysosomal movement associated disease in an animal, in which the position of lysosomes can influence disease progression, comprising administering an effective amount of a first lysosome migration inhibitor or a pharmaceutically acceptable salt, solvate, clathrate, stereoisomer, enantiomer or prodrug thereof.

  用于治疗动物溶酶体运动相关疾病的方法和组合物，其中溶酶体的位置可影响疾病的进展，包括施用有效量的第一溶酶体迁移抑制剂或其药学上可接受的盐、溶胶、凝胶体、立体异构体、对映体或原药。
• CANCER TREATMENT VIA REPOSITIONED TRICYCLIC ANTI-DEPRESSANT-LIKE DRUGS AS ANTI-CANCER AGENTS AND NEW COMBINATIONS OF SUCH DRUGS
  申请人：Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

  公开号：US20180133208A1

  公开（公告）日：2018-05-17

  Methods and compositions for treating a lysosomal movement associated disease in an animal, in which the position of lysosomes can influence disease progression, comprising administering an effective amount of a first lysosome migration inhibitor or a pharmaceutically acceptable salt, solvate, clathrate, stereoisomer, enantiomer or prodrug thereof.